WATERTOWN, Mass.--(BUSINESS WIRE)--Pandion Therapeutics, Inc., a clinical-stage, privately-held biotechnology company developing modular protein therapeutics for autoimmune diseases, today announced the appointment of John S. Sundy, M.D., Ph.D., as Chief Medical Officer.
“As a highly regarded drug developer and clinician, John’s experience in translational medicine will be instrumental to Pandion as we advance our lead clinical-stage program, PT101, a novel interleukin 2 (IL-2) mutein Fc fusion protein,” said Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics. “In addition, his depth of expertise in inflammation and immunology is a tremendous asset to Pandion as we build a robust and innovative pipeline focused on autoimmune and inflammatory diseases.”
Dr. Sundy brings extensive expertise in the development of investigational therapies, having most recently served as Senior Vice President and inflammation therapeutic area head at Gilead Sciences. There he led Gilead’s entry into inflammation and immunology and oversaw the clinical development of over a dozen new drug programs including filgotinib, which was filed for marketing authorization globally in rheumatoid arthritis in 2019. Previously, Dr. Sundy was Associate Professor of Medicine at Duke University and the Duke-National University of Singapore Graduate Medical School. While at Duke he was instrumental in the clinical development of Krystexxa®, which was approved in 2010 for patients with refractory gout. He also served as Associate Director of the Duke Clinical Research Institute and Director of Duke's Global Proof of Concept Research Unit Network in the US, Singapore and India. Dr. Sundy received his B.S. in biology from Bucknell University and his M.D. and Ph.D. from Drexel University School of Medicine.
“Pandion’s platform technology represents a truly innovative approach to regulating autoimmunity with modular proteins and bifunctional antibodies,” said Dr. Sundy. “I am excited to join the growing team at Pandion and advance our mission to bring transformative therapies to patients in need.”
About Pandion Therapeutics
Pandion Therapeutics is developing modular biologics for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases. The company is developing its lead drug candidate, PT101, an IL-2 mutein Fc fusion protein that preferentially expands regulatory T cells, as well as a robust pipeline of systemic immune modulators and tissue-targeted therapeutics focused on the gut, liver, skin, kidneys, and pancreas. Pandion’s approach to developing modular proteins, antibodies and bispecifics includes two key elements: first, the innovative biologics are based on cutting-edge immunomodulators such as an IL-2 mutein or PD-1 agonist that work systemically by activating regulatory pathways of the immune system that suppress uncontrolled autoimmune responses; and second, these immunomodulators can be combined with tissue-selective tethers, building modular proteins and antibodies that target the precise location within the organ to deliver the desired effect. Pandion is backed by leading life sciences investors and is headquartered in Watertown, Massachusetts. Please visit www.pandiontx.com.
